Stickler*
Active member
This may or may not be too technical for some. Regardless I thought this was pretty interesting. There has been huge debate/controversay regarding the prescribing of T3 for problematic thyroid patients vs using T4. However, concidering some people will self-prescribe this product to aid in weight loss during a cycle I thought it was worth mentioning.
It seems that apperently T3 dosage in accordance with certain anti-depressents has been used to increase and speed up the affects of the anti-depressents in regards to helping the treatment of depression. Please note as well that even these doctors use at least half of the diamond dosing (upwards with no mention of the downward side of dosing when doing a cycle of T3). It does not mention the affects after the study regarding thyroid condition after study patients came off of the T3 vs a placebo.
T3 for weightloss without the prescription or correct diagnoses from a doctor is not advised, but I put this here as just another source of information regarding the use of T3.
The final thought I wanted to put out there and ultimately ask people WHO HAVE USED T3.
1)Were you using anti-depresents while using it?
2)Do you remember ever feeling relief of certain stress related issues (maybe subconciously)
3)Regardless of anti-depressents, do you remember if you had a feeling a depression AFTER the usage of T3? (I ask, because depression worry after a cycle is always a concern - I'm curious if this could be a major factor depending on the popularity of this product in cycles anymore??)
---------------------------
T3 Supplementation Raises Patients' Response to Sertraline
JANE SALODOF MACNEIL
PARIS — Triiodothyronine supplementation significantly increased the antidepressant effects of sertraline in a randomized placebo-controlled clinical trial presented by Dr. Bernard Lerer in a breaking news session at the annual congress of the European College of Neuropsychopharmacology.
Israeli patients treated with sertraline (Zoloft) and triiodothyronine (T3) were nearly three times more likely to respond (odds ratio 2.93), compared with a cohort given sertraline and a placebo. Some 69.8% (37/53 patients) had at least a 50% reduction in their Hamilton Rating Scale for Depression (HAM-D) scores on the active drug combination vs. 50% (25/50 patients) in the control group.
The sertraline-T3 cohort also was much more likely (odds ratio 2.69) to go into remission by the sixth week of treatment. At that point, 58.5% (31/53) of the T3-augmented patients but only 38% (19/50) of the placebo group was in remission.
“Results of the current controlled study support the efficacy of T3 as an enhancer of antidepressant action,” said Dr. Lerer, director of the Hadassah Biological Psychiatry Laboratory and a professor of psychiatry at the Hadassah-Hebrew University Medical Center in Jerusalem.
Both groups of patients started on 50 mg per day of sertraline for 1 week, followed by 100 mg per day for 7 weeks. The T3 dose also was titrated up from 20–25 mcg per day the first week to 40–50 mcg per day for the rest of the trial.
T3's effects in the trial appeared to be related to the hormone's effect on thyroid function, according to Dr. Lerer. He said patients who responded to the active-drug combination tended to have lower baseline levels of T3 than those who did not. Patients who remitted on T3 and sertraline also had greater reductions in thyroid-stimulating hormone (TSH) than those who did not go into remission. Neither effect was seen in the sertraline-placebo group.
“The precise clinical role of T3 needs to be further defined, and predictors of response need to be identified,” Dr. Lerer said in his conclusion.
In September, an antidepressant trial in the United States reported that T3 augmentation resulted in more remissions and fewer adverse events than lithium augmentation in treatment-resistant patients (Am. J. Psychiatry 2006;163:1519–30). Reviewing this and previous studies of T3 and antidepressants, Dr. Lerer said researchers suspect patients with thyroid dysfunction are less able to respond to antidepressants. Prevalence of depression is higher in patients with hypothyroidism, he noted, whereas thyroid dysfunction is also more prevalent in patients with depression.
Though some studies have shown T3 to elicit responses more often in women than in men and also to speed response to antidepressants, Dr. Lerer said neither effect was seen in the new trial. He also reported no difference in adverse events with T3, compared with placebo.
Sertraline was chosen for the study because it is little used in Israel, Dr. Lerer said, and therefore, the trial was better able to enroll patients. Patients with clinical hyper- or hypothyroidism or other thyroid disorders, including subclinical hypothyroidism were excluded from the study.
The study received support from the Stanley Medical Research Institute in Chevy Chase, Md. Investigators from Beer Yaakov Mental Health Center in Israel and Global Medical Institutes in Princeton, N.J., also participated in the trial, which was coordinated by Dr. Lerer's group.
PII: S0270-6644(06)71858-6
doi:10.1016/S0270-6644(06)71858-6
© 2006 Elsevier Inc. All rights reserved.
It seems that apperently T3 dosage in accordance with certain anti-depressents has been used to increase and speed up the affects of the anti-depressents in regards to helping the treatment of depression. Please note as well that even these doctors use at least half of the diamond dosing (upwards with no mention of the downward side of dosing when doing a cycle of T3). It does not mention the affects after the study regarding thyroid condition after study patients came off of the T3 vs a placebo.
T3 for weightloss without the prescription or correct diagnoses from a doctor is not advised, but I put this here as just another source of information regarding the use of T3.
The final thought I wanted to put out there and ultimately ask people WHO HAVE USED T3.
1)Were you using anti-depresents while using it?
2)Do you remember ever feeling relief of certain stress related issues (maybe subconciously)
3)Regardless of anti-depressents, do you remember if you had a feeling a depression AFTER the usage of T3? (I ask, because depression worry after a cycle is always a concern - I'm curious if this could be a major factor depending on the popularity of this product in cycles anymore??)
---------------------------
T3 Supplementation Raises Patients' Response to Sertraline
JANE SALODOF MACNEIL
PARIS — Triiodothyronine supplementation significantly increased the antidepressant effects of sertraline in a randomized placebo-controlled clinical trial presented by Dr. Bernard Lerer in a breaking news session at the annual congress of the European College of Neuropsychopharmacology.
Israeli patients treated with sertraline (Zoloft) and triiodothyronine (T3) were nearly three times more likely to respond (odds ratio 2.93), compared with a cohort given sertraline and a placebo. Some 69.8% (37/53 patients) had at least a 50% reduction in their Hamilton Rating Scale for Depression (HAM-D) scores on the active drug combination vs. 50% (25/50 patients) in the control group.
The sertraline-T3 cohort also was much more likely (odds ratio 2.69) to go into remission by the sixth week of treatment. At that point, 58.5% (31/53) of the T3-augmented patients but only 38% (19/50) of the placebo group was in remission.
“Results of the current controlled study support the efficacy of T3 as an enhancer of antidepressant action,” said Dr. Lerer, director of the Hadassah Biological Psychiatry Laboratory and a professor of psychiatry at the Hadassah-Hebrew University Medical Center in Jerusalem.
Both groups of patients started on 50 mg per day of sertraline for 1 week, followed by 100 mg per day for 7 weeks. The T3 dose also was titrated up from 20–25 mcg per day the first week to 40–50 mcg per day for the rest of the trial.
T3's effects in the trial appeared to be related to the hormone's effect on thyroid function, according to Dr. Lerer. He said patients who responded to the active-drug combination tended to have lower baseline levels of T3 than those who did not. Patients who remitted on T3 and sertraline also had greater reductions in thyroid-stimulating hormone (TSH) than those who did not go into remission. Neither effect was seen in the sertraline-placebo group.
“The precise clinical role of T3 needs to be further defined, and predictors of response need to be identified,” Dr. Lerer said in his conclusion.
In September, an antidepressant trial in the United States reported that T3 augmentation resulted in more remissions and fewer adverse events than lithium augmentation in treatment-resistant patients (Am. J. Psychiatry 2006;163:1519–30). Reviewing this and previous studies of T3 and antidepressants, Dr. Lerer said researchers suspect patients with thyroid dysfunction are less able to respond to antidepressants. Prevalence of depression is higher in patients with hypothyroidism, he noted, whereas thyroid dysfunction is also more prevalent in patients with depression.
Though some studies have shown T3 to elicit responses more often in women than in men and also to speed response to antidepressants, Dr. Lerer said neither effect was seen in the new trial. He also reported no difference in adverse events with T3, compared with placebo.
Sertraline was chosen for the study because it is little used in Israel, Dr. Lerer said, and therefore, the trial was better able to enroll patients. Patients with clinical hyper- or hypothyroidism or other thyroid disorders, including subclinical hypothyroidism were excluded from the study.
The study received support from the Stanley Medical Research Institute in Chevy Chase, Md. Investigators from Beer Yaakov Mental Health Center in Israel and Global Medical Institutes in Princeton, N.J., also participated in the trial, which was coordinated by Dr. Lerer's group.
PII: S0270-6644(06)71858-6
doi:10.1016/S0270-6644(06)71858-6
© 2006 Elsevier Inc. All rights reserved.
